FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis
BackgroundDeng's Yangxin Decoction (DYX) is a Chinese herbal formula used in clinical practice to treat patients with myocardial infarction (MI). However, its underlying mechanism remains unclear.ObjectiveThis study aims to explore potential biomarkers and associated mechanisms of DYX for MI.Me...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1488684/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122450544623616 |
|---|---|
| author | Junfeng Fang Wei Wu Weifeng He Lin Wang Shiyi Liu |
| author_facet | Junfeng Fang Wei Wu Weifeng He Lin Wang Shiyi Liu |
| author_sort | Junfeng Fang |
| collection | DOAJ |
| description | BackgroundDeng's Yangxin Decoction (DYX) is a Chinese herbal formula used in clinical practice to treat patients with myocardial infarction (MI). However, its underlying mechanism remains unclear.ObjectiveThis study aims to explore potential biomarkers and associated mechanisms of DYX for MI.MethodsTherapeutic targets for DYX were obtained based on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Traditional Chinese Medicine Integrated Database, and UniProt databases. Key targets were screened using topological analysis. Differentially expressed genes (DEGs) between MI patients and controls were obtained using open-source datasets. Weighted gene co-expression network analysis (WGCNA) was utilized to screen MI-related genes in the expression array. Hub biomarkers were determined by intersecting DEGs, protein–protein interaction networks, and WGCNA results. Molecular docking validated interactions between DYX components and hub biomarkers. Immune infiltration was assessed via CIBERSORT. Single-cell RNA sequencing analyzed hub biomarker expression in coronary plaques.ResultsFOS was a core biomarker for DYX for MI. Molecular docking confirmed strong binding affinities between quercetin/baicalein and FOS. In addition, high expression of FOS was associated with immune infiltration of neutrophils, activated mast cells, activated dendritic cells, monocytes, and NK cells. FOS was also found to be expressed at high levels in mast and dendritic cells, monocytes, and some T cells in coronary plaques.ConclusionFOS is a target of DYX for the treatment of MI, and the mechanism of action may be related to the modulation of immune infiltration. |
| format | Article |
| id | doaj-art-1fb2fed8a0314c448b73a89a007b7587 |
| institution | OA Journals |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-1fb2fed8a0314c448b73a89a007b75872025-08-20T02:34:50ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-05-011210.3389/fcvm.2025.14886841488684FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysisJunfeng Fang0Wei Wu1Weifeng He2Lin Wang3Shiyi Liu4Department of Emergency Medicine, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Cardiovascular Medicine, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Emergency Medicine, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaDepartment of Emergency Medicine, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaBackgroundDeng's Yangxin Decoction (DYX) is a Chinese herbal formula used in clinical practice to treat patients with myocardial infarction (MI). However, its underlying mechanism remains unclear.ObjectiveThis study aims to explore potential biomarkers and associated mechanisms of DYX for MI.MethodsTherapeutic targets for DYX were obtained based on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Traditional Chinese Medicine Integrated Database, and UniProt databases. Key targets were screened using topological analysis. Differentially expressed genes (DEGs) between MI patients and controls were obtained using open-source datasets. Weighted gene co-expression network analysis (WGCNA) was utilized to screen MI-related genes in the expression array. Hub biomarkers were determined by intersecting DEGs, protein–protein interaction networks, and WGCNA results. Molecular docking validated interactions between DYX components and hub biomarkers. Immune infiltration was assessed via CIBERSORT. Single-cell RNA sequencing analyzed hub biomarker expression in coronary plaques.ResultsFOS was a core biomarker for DYX for MI. Molecular docking confirmed strong binding affinities between quercetin/baicalein and FOS. In addition, high expression of FOS was associated with immune infiltration of neutrophils, activated mast cells, activated dendritic cells, monocytes, and NK cells. FOS was also found to be expressed at high levels in mast and dendritic cells, monocytes, and some T cells in coronary plaques.ConclusionFOS is a target of DYX for the treatment of MI, and the mechanism of action may be related to the modulation of immune infiltration.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1488684/fullmyocardial infarctionimmune infiltrationbioinformatic analysissingle-cell analysisnetwork pharmacologydiagnostic biomarker |
| spellingShingle | Junfeng Fang Wei Wu Weifeng He Lin Wang Shiyi Liu FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis Frontiers in Cardiovascular Medicine myocardial infarction immune infiltration bioinformatic analysis single-cell analysis network pharmacology diagnostic biomarker |
| title | FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis |
| title_full | FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis |
| title_fullStr | FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis |
| title_full_unstemmed | FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis |
| title_short | FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis |
| title_sort | fos as a biomarker for myocardial infarction treatment with deng s yangxin decoction a systems biology based analysis |
| topic | myocardial infarction immune infiltration bioinformatic analysis single-cell analysis network pharmacology diagnostic biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1488684/full |
| work_keys_str_mv | AT junfengfang fosasabiomarkerformyocardialinfarctiontreatmentwithdengsyangxindecoctionasystemsbiologybasedanalysis AT weiwu fosasabiomarkerformyocardialinfarctiontreatmentwithdengsyangxindecoctionasystemsbiologybasedanalysis AT weifenghe fosasabiomarkerformyocardialinfarctiontreatmentwithdengsyangxindecoctionasystemsbiologybasedanalysis AT linwang fosasabiomarkerformyocardialinfarctiontreatmentwithdengsyangxindecoctionasystemsbiologybasedanalysis AT shiyiliu fosasabiomarkerformyocardialinfarctiontreatmentwithdengsyangxindecoctionasystemsbiologybasedanalysis |